Armata Pharmaceuticals (ARMP) Common Equity (2013 - 2026)
Armata Pharmaceuticals (ARMP) posted Common Equity of -$311.6 million for Q1 2026, down 42.54% sequentially from -$218.6 million in Q4 2025, and down 479.34% YoY from $82.1 million in Q1 2025.
Armata Pharmaceuticals (ARMP) Common Equity (2013 - 2026) Analysis & Trends
Armata Pharmaceuticals has reported Common Equity for 14 years, with the latest figure at -$311.6 million in Q1 2026.
- Quarterly Common Equity fell 479.34% year-over-year to -$311.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$311.6 million (down 479.34% YoY) and the FY2025 annual result came in at -$218.6 million, down 355.23% from the prior year.
- Common Equity fell to -$311.6 million in Q1 2026 per ARMP's latest filing, from -$218.6 million in the prior quarter.
- Over five years, Common Equity peaked at $61.5 million in Q1 2022 and troughed at -$311.6 million in Q1 2026.
- A 5-year average of -$44.5 million and a median of -$46.1 million in 2024 frame the typical range for Common Equity.
- The sharpest annual moves came in 2022 and 2026: Common Equity jumped 91.86% in 2022, then plunged 479.34% in 2026.
- Over 5 years, Common Equity stood at $36.1 million in 2022, then slumped by 188.87% to -$32.1 million in 2023, then sank by 49.76% to -$48.0 million in 2024, then slumped by 355.23% to -$218.6 million in 2025, then slumped by 42.54% to -$311.6 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered -$311.6 million, -$218.6 million, and -$95.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Armata Pharmaceuticals | 162.98 Mn | 138.98 Mn | - | -231.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -231.17 Mn |
| Mar 31, 2026 | -311.59 Mn |
| Dec 31, 2025 | -218.60 Mn |
| Sep 30, 2025 | -95.59 Mn |
| Jun 30, 2025 | -69.50 Mn |
| Mar 31, 2025 | -53.78 Mn |
| Dec 31, 2024 | -48.02 Mn |
| Sep 30, 2024 | -50.97 Mn |
| Jun 30, 2024 | -46.10 Mn |
| Mar 31, 2024 | -56.51 Mn |
| Dec 31, 2023 | -32.07 Mn |
| Sep 30, 2023 | -12.39 Mn |
| Jun 30, 2023 | 19.14 Mn |
| Mar 31, 2023 | 22.45 Mn |
| Dec 31, 2022 | 36.08 Mn |
| Sep 30, 2022 | 45.58 Mn |
| Jun 30, 2022 | 53.29 Mn |
| Mar 31, 2022 | 61.54 Mn |
| Dec 31, 2021 | 25.40 Mn |
| Sep 30, 2021 | 23.76 Mn |